Dr. Fatima Khalid Alduraibi, MD, PhD

Dr. Alduraibi practices at Beth Israel Deaconess Medical Center in Boston, Massachusetts, part of Beth Israel Lahey Health.

Dr. Alduraibi's NPI, 1285155135, was assigned on June 30, 2017. Dr. Alduraibi holds Massachusetts license 295273.

Dr. Alduraibi's primary practice is Beth Israel Deaconess Medical Center, at 330 Brookline Avenue, Boston, MA 02215 in Suffolk County. The practice phone is (617) 667-7000.

Dr. Alduraibi's primary practice is Beth Israel Deaconess Medical Center in Boston, Massachusetts, part of Beth Israel Lahey Health. The medical group on file is Harvard Medical Faculty Physicians at Beth Israel Deaconess Medical Center (HMFP). Dmand AI also links Dr. Alduraibi to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Alduraibi practices, 2 sites in all. Vendor and product names are available with a free account.

Rheumatology is Dr. Alduraibi's primary specialty in the NPI Registry, under taxonomy code 207RR0500X. Dmand AI has Dr. Alduraibi's licenses on file in 2 states: Massachusetts and Virginia.

CMS data shows 103 Medicare services from Dr. Alduraibi across 4 procedure codes in 2024, all of them office visits, for 66 Medicare patients. Medicare paid $10,936 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 66 Medicare patients who saw Dr. Alduraibi in 2024. The largest group is 65 to 74, with 25 patients. 75% of them have arthritis, and 73% have high cholesterol. 30% are also on Medicaid. Their average risk score is 1.54, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Alduraibi's median patient age at 71, with 64% women.

In 2024, Dr. Alduraibi wrote 253 Medicare Part D claims for 55 patients. 77% of them were for generic drugs. CMS names the drug for 177 of them, across 6 drugs with 11 or more claims each, at $285,577 in total drug cost. In 2023, CMS named 79 claims across 3 drugs.

Dmand AI links 9 papers to Dr. Alduraibi, published from 2022 to 2024. 2022 was the busiest year, with 3. The most frequent topics are Lupus Erythematosus, Systemic, Autoantibodies and Interferon-gamma. Dr. Alduraibi has published most often in Clin Immunol. Dr. Alduraibi's most frequent co-authors are Walter Chatham, Jasvinder Singh and Haneen Abdalhadi, MD.

CMS Open Payments shows 4 general payments to Dr. Alduraibi from 2 drug and device companies from 2019 to 2023. Food and beverage make up the largest share, 78% of the total. GlaxoSmithKline, LLC. paid the most, $122.